



ABN 53 075 582 740

ASX ANNOUNCEMENT
16 May 2013

CTX AND BIONOMICS' PROGRAM REACHES KEY MILESTONE

- **Proof of concept in model of melanoma**

Bionomics Limited (ASX: BNO, ADR: BMICY) has today announced that its joint program with the Co-operative Research Centre for Cancer Therapeutics (CTx) has reached a proof of concept milestone in the discovery and preclinical evaluation of inhibitors of vascular growth factor receptor 3 (VEGFR3).

CTx-0357927, a compound from the collaborative program, has suppressed cancer progression as indicated by tumour growth inhibition and number of identified metastases in an animal model of melanoma. This model of human melanoma forms primary melanoma lesions that metastasize to the regional lymph nodes and enables the evaluation of a compound's ability to suppress both primary tumour growth and lymph node metastasis.

The activation of VEGFR3 is closely linked to the development of lymphatic vessels. Lymphatic vessels are important for the metastasis of cancer as they act as a conduit for tumour cells that spread to distant sites around the body. Tumours, such as melanoma and breast cancer, activate VEGFR3 to increase the growth of lymphatic vessels to enable tumour cells to spread. The majority (90%) of cancer deaths are caused by cancer that has spread from the original site (metastatic disease) and targeting the mechanisms that encourage metastasis will be key to further reducing cancer deaths.

US figures suggest that the overall 5-year survival rate for patients whose melanoma is detected early, before the tumour has spread to regional lymph nodes or other organs, is about 98 percent. The survival rate falls to 62 percent when the disease reaches the lymph nodes, and 15 percent when the disease metastasizes to distant organs.

CEO and Managing Director of Bionomics Dr Deborah Rathjen said "VEGFR3 inhibitors such as CTx-0357927 have potential in the treatment of melanoma and in breast cancer. It is pleasing to reach this milestone and to see this encouraging data from an animal model of melanoma".

Melanoma is the fourth most common cancer reported in Australia. In 2008, there were 11,057 new cases of melanoma of the skin in Australia accounting for 9.8 per cent of all new cancers.

Bionomics has been a key commercial and research partner with CTx since 2007.

Dr Warwick Tong, CTx CEO said "this program is a great example of how the collaborative research model fostered by the CRC Program combines the expertise from a group of research and commercial partners to produce novel cancer drugs".

Details of the anti-tumour activity of CTx-0357927 are shown in the Appendix accompanying this announcement.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule and antibody product development programs in the areas of cancer, anxiety, and memory loss. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

About Cancer Therapeutics CRC: Cancer Therapeutics CRC (CTx) is a small molecule drug discovery company that is translating innovative cancer biology research into lead and preclinical stage drug candidates. In particular it is targeting novel cancer pathways associated with the tumour microenvironment or growth, and to develop novel treatments for breast, prostate, melanoma, lung and brain cancers. Located in Melbourne, Australia, the Company was founded in January 2007 through a collaboration between a number of Australia's leading research institutions, and commercial organisations.. Further information can be found at www.cancercrc.com.


About CRC Australia: The Cooperative Research Centres (CRC) program is an Australian Government Initiative. The CRC program supports end-user driven research collaborations to address the major challenges facing Australia.
www.crc.gov.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.

Appendix

CTX-0357927 inhibits tumour metastasis in the B16F10 melanoma model:



CTX-0357927 inhibits tumour growth in the B16F10 melanoma model:

